Hoffmann-la Roche

This study tests a drug called crovalimab in 41 children with atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and kidney damage. The goal is to see if the drug can control the disease and improve kidney function. Participants receive crovalimab…

This study tests whether the immunotherapy drug atezolizumab can help prevent lung cancer from returning in people with stage IB to IIIA non-small cell lung cancer who have already had surgery and chemotherapy. About 1,280 participants will receive either atezolizumab for 16 cycl…

This study tests a new drug called giredestrant against standard hormone therapies in over 4,000 people with early-stage, hormone-sensitive breast cancer. The goal is to see if giredestrant is better at stopping the cancer from coming back. Participants take the drug daily for se…

This early-stage study tests a new medicine called RO7790121 in 50 adults with advanced liver scarring (fibrosis) caused by MASH. The main goal is to check the drug's safety and how the body processes it. Participants must have a certain body mass index and liver stiffness level.…

This study tests a new drug called RO7790121 in about 21 adults with moderate to severe Crohn's disease who haven't responded well to standard treatments. The goal is to see if the drug can reduce gut inflammation and improve symptoms like diarrhea and stomach pain. Participants …

This study tests a new drug called glofitamab added to standard chemotherapy (R-CHOP) for people with a high-risk type of lymphoma (DLBCL) who have not been treated before. The goal is to see if the combination is safe and helps more patients achieve complete remission. About 46 …

This study tests a new drug called giredestrant against standard hormone therapies for people with a common type of advanced breast cancer (ER+/HER2-). About 300 participants who have already tried one or two prior treatments will be randomly assigned to receive either giredestra…

This study tests whether a combination of two drugs (atezolizumab and bevacizumab) can prevent liver cancer from returning in people who have had surgery or ablation to remove their tumor. About 668 participants at high risk of recurrence will receive either the drug combination …

This study tests a daily pill called giredestrant in 30 people with Grade 1 endometrial cancer (a low-grade uterine cancer). The goal is to see if the drug can shrink or stop the cancer from growing over 6 months, possibly avoiding or delaying surgery. Participants take the drug …

This study tests a new once-daily medicine called RO7795081 to see if it helps lower blood sugar in adults with type 2 diabetes. About 240 participants will take the study drug, a placebo (inactive pill), or an approved diabetes medicine (semaglutide) for 30 weeks. The main goal …

This study tests a drug called satralizumab in 30 children (ages 8 to 17) with Duchenne muscular dystrophy who are already taking steroids. The goal is to see if the drug can improve bone density and is safe. The study is active but not recruiting new participants.

This early-stage study tests a new drug, RO7247669, that works like a double-pronged key to help the immune system attack cancer cells. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options will r…

This study follows 1,200 people in China newly diagnosed with advanced non-small-cell lung cancer (stage IIIB/IIIC/IV) that cannot be removed by surgery. Researchers will collect information from medical records and follow patients over time to see what treatments doctors use, ho…